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Background: Rodents are incapable of emesis and consequently the emetic potential of glucagon-like peptide-1
receptor (GLP-1R) agonists in studies designed to assess a potential blood glucose lowering action of the
compound was missed. Therefore, we investigated if the ferret, a carnivore with demonstrated translation capability
in emesis research, would identify the emetic potential of the GLP-1R agonist, exendin-4, and any associated effects
on gastric motor function, appetite and cardiovascular homeostasis.
Methods: The biological activity of the GLP-1R ligands was investigated in vivo using a glucose tolerance test in
pentobarbitone-anesthetised ferrets and in vitro using organ bath studies. Radiotelemetry was used to investigate the
effect of exendin-4 on gastric myoelectric activity (GMA) and cardiovascular function in conscious ferrets; behaviour
was also simultaneously assessed. Western blot was used to characterize GLP-1R distribution in the gastrointestinal and
brain tissues.
Results: In anesthetised ferrets, exendin-4 (30 nmol/kg, s.c.) reduced experimentally elevated blood glucose levels by
36.3%, whereas the GLP-1R antagonist, exendin (9–39) (300 nmol/kg, s.c.) antagonised the effect and increased
AUC0–120 by 31.0% when injected alone (P < 0.05). In animals with radiotelemetry devices, exendin-4 (100 nmol/kg, s.c.)
induced emesis in 1/9 ferrets, but inhibited food intake and decreased heart rate variability (HRV) in all animals
(P < 0.05). In the animals not exhibiting emesis, there was no effect on GMA, mean arterial blood pressure, heart rate,
or core body temperature. In the ferret exhibiting emesis, there was a shift in the GMA towards bradygastria with a
decrease in power, and a concomitant decrease in HRV. Western blot revealed GLP-1R throughout the gastrointestinal
tract but exendin-4 (up to 300 nM) and exendin (9–39), failed to contract or relax isolated ferret gut tissues. GLP-1R
were found in all major brain regions and the levels were comparable those in the vagus nerve.
Conclusions: Peripherally administered exendin-4 reduced blood glucose and inhibited feeding with a low emetic
potential similar to that in humans (11% vs 12.8%). A disrupted GMA only occurred in the animal exhibiting
emesis raising the possibility that disruption of the GMA may influence the probability of emesis occurring in
response to treatment with GLP-1R agonists.
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Glucagon-like peptide-1 (GLP-1) is a hormone secreted
by the small intestine in response to nutrient ingestion [1].
It exerts its biological actions via G-protein-coupled
receptors, which are members of the glucagon receptor
superfamily, including glucagon, glucagon-like peptide-2,
glucose-dependent insulinotropic peptide, growth hormone-
releasing hormone, and secretin [2]. Activation of GLP-1
receptors reduces blood glucose levels by stimulating
glucose-induced insulin secretion and suppressing gluca-
gon production [3,4]. In addition, there is an inhibition of
gastric emptying [5] and small bowel motility [6], with
studies reporting a decrease of appetite and a reduction of
food intake [7,8].
GLP-1 analogues have been investigated for the treat-
ment of type-2 diabetes and obesity [9]. However, the use
of such agents was commonly associated with nausea and
emesis (vomiting) thus limiting their clinical development
[10,11] as illustrated by the withdrawal of a GLP-1 analog
in a phase III clinical trial because of the high incidence of
nausea and vomiting [12]. The mechanisms and pathways
by which GLP-1 receptors induce emesis are not known
and this is partially because most preclinical research on
GLP-1 used species incapable of emesis, such as rats and
mice [13-15]. In these species, GLP-1 clearly reduces
plasma glucose levels at doses that are known to delay
gastric emptying and cause hypertension [16,17]. How-
ever, studies using the house musk shrew (Suncus muri-
nus), an insectivore capable of emesis, have shown that
the GLP-1 agonist, exendin-4 can lower blood glucose
levels, elevate plasma insulin, induce emesis, and contract
the isolated ileum via a mechanism involving the enteric
nervous system [18-20].
To gain an insight into the mechanisms involved in the
emetic dose-limiting toxicity of GLP-1 receptor agonists,
we undertook a series of studies in the ferret, a species
with a well characterised emetic response, sensitivity to a
diverse range of emetic agents and demonstrated transla-
tion potential in efficacy of anti-emetic drugs [21,22].
Initially, the presence of GLP-1 receptors was estab-
lished in the brain and gut and the effect of exendin-4
on isolated gut regions investigated. The biological ac-
tivity of the GLP-1 receptor agonist exendin-4, and the
GLP-1 receptor antagonist, exendin (9–39), was demon-
strated in vivo using a glucose tolerance test [23]. As gas-
tric dysrhythmia has been associated with nausea and
emesis induced by a variety of treatments [24], we used
telemetry to investigate the effect of exendin-4 on the gas-
tric myoelectric activity (GMA) in conscious ferrets [25]
and combined this with measurement of heart rate vari-
ability, an index of autonomic nervous system activity
frequently monitored in human studies of nausea and
vomiting [26,27], thus permitting further assessment of
the potential for ferret data to translate to humans.Methods
Animals
Twenty-eight castrated male fitch ferrets (1.51 ± 0.05 kg)
were obtained from Southland Ferrets (Invercargill, New
Zealand) and housed in a temperature-controlled room at
24 ± 1°C under artificial lighting, with lights on between
06:00 to 18:00 h. The relative humidity was maintained at
50 ± 5 %. Water and food (TriPro super premium chicken
meal formula dog food, American Nutrition, USA) were
given ad libitum unless otherwise stated. All experiments
were conducted under licence from the Government of
Hong Kong SAR and the Animal Experimentation Ethics
Committee, The Chinese University of Hong Kong.Western blot
Animals (n = 3) were fasted overnight and then killed
using pentobarbitone (80 mg/kg, i.p.) (Dorminal®, Alfasan,
Woerden, Holland). The whole gastrointestinal tract was
removed and immediately washed in freshly prepared
Krebs solution (composition in mM: NaCl 118, KCl 4.7,
KH2PO4 1.2, MgSO4•7H2O 1.2, CaCl2•2H2O 2.5,
NaHCO3 25 and glucose 10) (Merck, Germany) and
gassed with 95% O2 and 5% CO2 at room temperature;
cervical vagi and brains were also removed. Segments of
the gastrointestinal tract, the cervical vagi, and selected
brain areas [28] were lysed in sodium dodecyl sulphate
(SDS) lysis buffer containing protease inhibitor cocktail
tablets (Complete Mini, Roche). The protein concentra-
tions of each extract was measured using a Bio-Rad Pro-
tein Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA)
according to manufacturer’s instructions, and 12.5 μg of
brain tissues or 25 μg of vagus or gut tissues were added
to 10% polyacrylamide gels. Gels were then transferred to
nitrocellulose membranes, blocked by incubating them
with 5% bovine serum albumin in washing buffer for 1 h
at room temperature, and then incubated overnight at 4°C
with primary antibodies directed against the GLP-1 recep-
tors (ab13181, 1:1000, Abcam, Inc., Cambridge, MA). This
antibody reacts with mouse, rat, dog and human GLP1 R
but no data are available on its specificity for the ferret
receptor. Rat brain tissue was used as a positive control
for the antibody (data not shown). Membranes were
washed 3 times with 5 min intervals, incubated with anti-
rabbit IgG horseradish peroxidise conjugate (1:2000,
Thermo Scientific, Rockford, USA) for 1 h, and washed
again (4 × 5 min) before incubating with a chemilumines-
cence detection reagent for 5 min. The protein was visua-
lised by exposing the membrane to a ChemDoc XRS
detection system (Bio-Rad, Milan, Italy). GAPDH served
as an internal control, and it was similarly detected using
a horseradish peroxidase conjugated mouse anti-GAPDH
as the primary antibody. Band intensity was analysed and
GLP-1 receptor expression was calculated as the ratio of
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intensity in the same blot [29].
Organ bath studies
One centimetre segments of circular antrum, longitudinal
duodenum, jejunum, ileum and colon were dissected from
animals killed for the Western blot study (see above). The
segments with intact mucosa were mounted longitudinally
under 0.5 g resting tension in a 10 ml organ bath contain-
ing Krebs solution and gassed with 95% O2 and 5% CO2 at
37°C [30]. The isometric contractions of tissues were re-
corded using Grass transducers via a MacLab® system
(ADInstruments Pty Ltd., New South Wales, Australia )
connected to a Power Macintosh G3 computer (Apple
Computer, Inc., California, U.S.A.). Analytical software
(Chart, version 3.5 s/s MacLab®, New South Wales,
Australia) was used to display and analyse the ampli-
tude and frequency of the contractions. The contractile
responses were measured by the change of tension (g)
before and after the addition of drugs. The frequency of
contractions was measured over a period of 1 min be-
fore and after drug administration. After 30 min, KCl
(120 mM) was added to provide a reference contractile
response followed by washout.
After 60 min of equilibration, increasing concentrations
of exendin-4 (0.03-300 nM) were added to the organ bath
cumulatively using a 2–6 min dosing schedule. KCl
(120 mM) was added again to check the viability and con-
tractility of the tissues. In some experiments, gut tissues
(circular antrum, longitudinal jejunum, duodenum, ileum,
and colon) were pre-contracted using carbachol (10 μM).
After reaching a stable maximum contraction, increasing
concentrations of exendin-4 (0.03-300 nM) were added
cumulatively using a 2–6 min dosing schedule. At the end
of each experiment, carbachol was washed out followed by
adding KCl (120 mM) to check the viability of the tissues.
A separate set of experiments examined the effect of
exendin-4 on tissues contracted by electrical field
stimulation (EFS). Briefly, after equilibration, gut tissues
contracted by EFS to produce a sub-maximal contrac-
tion. The EFS parameters were: train duration, 5 sec;
voltage, 50 V; pulse width, 0.5 ms; frequency, 10 Hz;
interval, 1 min. After reaching a stable contraction,
exendin-4 (300 nM) or atropine (1 μM) was added. At
the end of each experiment, EFS was stopped and KCl
(120 mM) was added to check the viability of the gut
tissues. The volume of drug solutions added to the
organ bath was less than 0.3% of the total bath volume.
Blood glucose tolerance test
Twelve ferrets were fasted overnight and then anaesthe-
tised with pentobarbitone (40 mg/kg, i.p.) to a depth suffi-
cient to abolish the pedal reflex. Blood samples were
collected by tail vein puncture at 5 to 20 min intervals andanimals were randomized using Latin square design into
four treatment groups (n = 3 per group). Saline (0.5 ml/kg)
or exendin (9–39) (300 nmol/kg) was administered sub-
cutaneously (25G, scruff of the neck). Fifteen minutes
later, saline (0.5 ml/kg, s.c.) or exendin-4 (30 nmol/kg, s.c.)
was injected, followed immediately by a glucose load
(1.5 g/kg, i.p.). Blood sampling was continued for up to
2 h but as only one drop of blood was required for the
glucose analysis saline replacement was not considered
necessary. Blood glucose was measured immediately via a
glucose oxidase-based method using a Glucometer Elite
blood glucose meter (Bayer, Mishawaka, USA). Animals
were killed at the end of the experiment with and over-
dose of pentobarbitone (80 mg/kg, i.p.).
Implantation of radiotelemetric devices
Thirteen ferrets were fasted overnight but allowed free
access to water. They were then injected with buprenor-
phine (0.05 mg/kg, s.c. Temgesic®), and anaesthesia was
induced by ketamine (20 mg/kg i.m.; Alfasan, Holland)
and maintained with 1.5% isoflurane (Halocarbon Prod-
ucts Corporation, USA) in O2 using a custom-made face
mask and an anaesthetic machine (Narkomed 2C, Drager,
USA). Animals were placed on a heating pad (UCI#390
Analogue moist heating pad, Rebirth Medical & Design,
Inc., Taiwan) and the level of anaesthesia was assessed and
monitored throughout the surgery by the pedal with-
drawal reflex. Following a midline abdominal incision, a
19G needle was used to pierce the aorta, and then the
catheter of a C50-PXT transmitter (Data Sciences, Inc,
USA) was inserted up to a length of approximately 2 cm.
A 2 × 2 mm piece of sterile gauze was placed over the
catheter’s entry point, and fixed with a drop of tissue glue.
The body of the transmitter was then sutured to the left
side of the ferret’s abdominal wall muscle with the biopo-
tential wires and catheter facing caudally. The gastric an-
trum was exposed and the biopotential wires were inserted
into the muscle and secured in place by suturing the serosa.
The abdominal cavity was sutured in closed layers and cov-
ered with a permeable spray dressing (Opsite®, Smith and
Nephew, UK). Marbofloxacin (Marbocyl®, 2 mg/kg, s.c.)
was administered once per day for 3 days and buprenor-
phine (0.05 mg/kg, s.c.) was given 8–12 h after the first
dose. Animals were allowed to recover for seven days
before drug treatment.
Effects of food intake on gastric myoelectric activity and
other physiological parameters
Four ferrets implanted with telemetry transmitters were
used in a crossover design to assess the effect of food
intake. Ferrets were fasted for 5 h, then at t = 5 h, animals
were either presented with a food bowl containing 20 g of
food (challenge A), or with an empty food bowl and
remained under fasting conditions for a further 2 h
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between the two challenges, the order of the challenges
were randomised for each animal using a coin flipping
strategy. At the end of experiment, animals were killed
by an overdose of pentobarbitone (80 mg/kg, i.p.).
Effects of exendin-4 (100 nmol/kg, s.c.) on emesis, food
intake, gastric myoelectric activity, core temperature and
the cardiovascular system
Nine ferrets were fasted overnight, and at 8:00 am they
were presented with 20 g of food for 30 min. At 8:30 am,
ferrets were fasted again. At 10:00 am (t = 0), they were
either injected with saline (0.5 ml/kg, s.c.) or exendin-4
(100 nmol/kg, s.c.) in a crossover design with a seven day
interval, the order of the challenges were randomised
for each animal using a coin flipping strategy. At
2:00 pm (t = 4 h), ferrets were given 20 g of food. The
amount of food eaten from 8:00 am to 8:30 am and
from 2:00 pm to 3:00 pm was measured. At 3:00 pm,
ferrets had free access to food until the end of the ex-
periment (10 am the next day). During the experiment,
physiological data were continuously acquired and em-
esis data were assessed for 4 h after drug injection.
Data analysis
Prior to any statistical comparisons, the normality of the
data was assessed with a Kolmogorov-Smirnov test. In the
blood glucose tolerance test, the total area under the curve
(AUC) for glucose was calculated using the trapezoidal
rule and the significance of differences between treat-
ments were assessed using one-way ANOVA followed by
Bonfferoni multiple comparison tests. All telemetric data
were processed using Spike2 (Version 7, Cambridge Elec-
tronic Design). The method for telemetric GMA data ana-
lysis had been described in previous studies; dominant
power (DP) was defined as the highest power in the 0 to
15 cpm range, and dominant frequency (DF) was defined
as the frequency bin with the highest power in the 0 to
15 cpm range [25]. Systolic blood pressure (BP) was calcu-
lated from the peak of the blood pressure recording trace
and diastolic BP was calculated from the trough of the BP
recording trace. Mean arterial BP was defined as Systolic
BP/3 + 2*Diastolic BP/3 [31]. For heart rate (HR), the peak
to peak interval was first calculated, and HR = 60/P-P
interval (bpm). The standard deviation of N-N intervals
(SDNN) was measured from the P-P wave interval of the
BP in five minute segments and is used as an index of
HRV [32]. Core body temperature (CBT) data were calcu-
lated by taking the average of the data. All the data were
averaged in 1 h segments for statistical analysis. The
differences of mean arterial BP, HR, HRV, CBT and
GMA between saline and exendin-4 treatment groups
and between food challenges were assessed using
repeated two-way ANOVA and Bonferroni tests. Theresponses of the gut tissues were measured by the dif-
ference in the change in tension (g) before and after the
addition of drugs. Responses were normalised and
expressed as a percentage of the reference response
produced by KCl. The significance of differences be-
tween data was determined using two-way ANOVA
followed by Bonferroni tests. All data are expressed as
mean ± s.e.m. Differences were considered statistically
significant when P < 0.05. All statistical analyses were
performed using GraphPad Prism version 5 (GraphPad
Prism version 5.0, Inc. Version California, USA).
Drug formulation
Exendin-4 and exendin (9–39) amide (American Pep-
tide Company, Sunnyvale, CA) were dissolved in saline
(0.9% w/v). Glucose (Merck, Darmstadt, Germany) was
dissolved in saline (0.9% w/v NaCl, 154 mM) and
administered in a volume of 0.5 ml/kg, i.p. Atropine
methyl nitrate and carbachol chloride (Sigma, Saint
Louis, USA) were dissolved in saline (0.9% w/v).
Results
Distribution of GLP-1 receptors
GLP-1 receptors were present in all regions of the brain
and the gastrointestinal tract that were examined. Within
the brain there was little variability in receptor distribution
but in the gastrointestinal tract there was a clear regional
differences in distribution with the highest density in the
colon and the lowest in the ileum (Figure 1). Overall the
density of GLP-1 receptors was approximately twice as
high in the central nervous system compared to the
gastrointestinal tract; these differences were not statisti-
cally significant (P > 0.05; n = 3, Figure 1).
Effect of exendin-4 on the isolated gut tissues
The gut tissues exhibited regular spontaneous contrac-
tions, and the frequency and amplitude are shown in
Table 1. KCl (120 mM) induced a rapid and reversible
contraction in all gut regions, with the maximal re-
sponse being observed within 5 sec (see Table 1).
Exendin-4 (0.03-300 nM) failed to either contract any
region of the gut or modify the amplitude and frequency
of the spontaneous contractions (n = 3 for each region).
In further experiments, therefore, carbachol (10 μM)
was used to induce a contraction of the ileum to
investigate if exendin-4 had a potential to induce
relaxation of tissues. Carbachol produced a sustained
contraction (see Table 1) but exendin-4 (0.03-300
nM) failed to affect the carbachol-induced contraction
(n = 3). A final set of experiments examined the effect
of exendin-4 on electrical field stimulated (EFS) con-
tractions of the gut. The amplitude of EFS-induced
contractions is shown in Table 1, but exendin-4 (100
nM) was without effect on the EFS-induced
Figure 1 The distribution of GLP-1 receptors in ferret brain and gastrointestinal tissues. AMY, amygdala; CER, cerebellum; FC, frontal
cortex; HIP, hippocampus; HYPO, hypothalamus; MB, midbrain; MED, medulla; PON, pons; STR, striatum; TH, thalamus; TC, temporal cortex; VG,
cervical vagus nerve; COR, gastric corpus (body); ANT, gastric antrum; DUO, duodenum; JEJ, jejunum; ILE, ileum; COL, colon. Data represents the
mean ± s.e.m. of 3 animals.
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Conversely, atropine (1 μM) significantly reduced the amp-
litude of the EFS-induced contractions by 73.2% ±9.0%,
71.9% ±10.0% , 64.4% ±9.7% , 52.0% ±5.1% , 77.5% ±3.6% in
the isolated segments of antrum, duodenum, jejunum,
ileum and colon (n = 3), respectively (P < 0.05; n = 3).
Representative tracings from the ileum are shown in
Figure 2.
Blood glucose tolerance test
The basal blood glucose level was 5.1 ± 0.3 mmol/l
(pooled data, n = 12; Figure 3A). The administration of
exendin (9–39) or saline had no effect on blood glucose
levels (AUC-15 – 0 values were not different between treat-
ment groups, P > 0.05; Figure 3B). However, the administra-
tion of glucose (1.5 g/kg, i.p.) at t = 0 in the saline-treated
animals caused a progressive elevation of blood glucose,
which peaked at 20 min (max level was 12.1 ±Table 1 Summary of the contraction frequency and amplitud
Frequency of spontaneous
contractions (cycles/min)
Amplitude of
spontaneous
contractions (g
Antrum 8.65 ± 0.23 0.62 ± 0.14
Duodenum 17.02 ± 0.20 0.70 ± 0.11
Jejunum 20.01 ± 0.12 0.69 ± 0.21
Ileum 18.25 ± 0.25 0.69 ± 0.21
Colon 15.78 ± 0.36 0.88 ± 0.30
Data represents the mean ± s.e.m. of 3 animals.0.7 mmol/l, n = 3), and then decreased gradually there-
after (Figure 3A). In animals treated with exendin-4
(30 nmol/kg, s.c.), the effect was reduced; the AUC0–120
value was decreased by 36.6% (saline/saline 1124.0 ±
126.3 vs. saline/exendin-4 716.5 ± 123.0 mmol•min/l,
P < 0.01; n = 3, Figure 3C). Administration of exendin
(9–39) (300 nmol/kg, s.c.) 15 min prior to exendin-4
prevented the glucose lowering effect of exendin-4
(AUC0–120 values: saline/saline 1124.0 ± 126.3 vs. exendin
(9–39)/exendin-4 986.9 ± 20.9 mmol•min/l, P > 0.05; n = 3,
saline/exendin-4 716.5 ± 123.0 vs. exendin (9–39)/exendin-
4 986.9 ± 20.9 mmol•min/l, P <0.05; n = 3, Figure 3C).
However, administration of exendin (9–39) alone increased
the blood glucose levels, with a significant increase be-
ing observed at 30 min after the glucose load (P < 0.05;
Figure 3A). Thus, the AUC0–120 value was potentiated by
31.1% (saline/saline 1124.0 ± 126.3 vs. exendin (9–39)/
saline 1473.0 ± 24.5 mmol•min/l, P <0.01; n = 3, Figure 3C).e of the gastrointestinal tract tissues in vitro
)
Amplitude
of KCl
response (g)
Amplitude of
carbachol
response (g)
Amplitude of
EFS-induced
response (g)
5.46 ± 0.33 2.33 ± 0.18 2.48 ± 0.72
4.12 ± 0.55 1.77 ± 0.12 0.96 ± 0.30
5.01 ± 0.27 2.80 ± 0.21 0.99 ± 0.09
4.28 ± 0.11 1.19 ± 0.17 0.65 ± 0.12
6.25 ± 0.61 4.37 ± 0.70 2.69 ± 0.91
AB
C
Figure 2 Representative tracings illustrating the contractile responsiveness of ferret ileum to exendin-4, carbachol, electrical field
stimulation (EFS) and atropine. (A) Effect of exendin-4. (B) Effect of exendin-4 on the carbachol pre-contracted ferret ileum. (C) Effect of
exendin-4 and atropine on the EFS pre-contracted ferret ileum. Ex-4 = exendin-4. Each black dot represents an EFS event.
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temperature and gastric myoelectric activity
Telemetered ferrets have not been used extensively in stud-
ies on feeding, cardiovascular and gastrointestinal studies.
Therefore, to provide a baseline for studies of exendin-4 we
performed a preliminary study to investigate the effect of
food intake itself on several physiological parameters in
animals that had been fasted for 5 h.
During fasting, ferrets had a basal mean arterial blood
pressure of 128.5 ± 2.5 mmHg (systolic blood pressure
161.9 ± 1.8 mmHg; diastolic blood pressure 113.9 ±
0.9 mmHg) heart rate and heart rate variability was
238.6 ± 3.4 bpm and 0.079 ± 0.002 (arbitrary units), re-
spectively (n = 3); core body temperature was 37.9 ±
0.1°C (n = 4, 2 replicates per animal). The baseline
GMA recordings revealed a DF of 9.6 ± 0.1 cpm and a
DP of 0.0019 ± 0.0006 mV2; 15.3 ± 2.8% of power was in
the bradygastric range, 61.4 ± 4.1% of power was in the
normogastric range, and 14.1 ± 0.7% of power was in
the tachygastric range (n = 4, 2 replicates per animal).
Feeding did not affect any of the cardiovascular param-
eters measured, or core body temperature (data not
shown, n = 3). However, there was a decrease in DF to8.9 ± 0.2 cpm, and a 30.3% increase of bradygastria, and
a 41.2% decrease in normogastria in the animals that
ate food (P < 0.001; n = 4, Figures 4 and 5).
The emetic potential of subcutaneously administered
exendin-4, and its ability to modify feeding, cardiovascular
function, core body temperature, and gastric myoelectric
activity
Ferrets had a basal arterial blood pressure of 108.6 ±
2.5 mmHg (systolic blood pressure: 136.5 ± 3.2 mmHg;
diastolic blood pressure: 92.3 ± 2.2 mmHg); heart rate
and heart rate variability were 222.8 ± 4.9 bpm and
0.071 ± 0.003 (arbitrary units), respectively; core body
temperature was 38.5 ± 0.1°C (n = 8, 2 replicates per ani-
mal). The baseline GMA recordings revealed a DF of
8.9 ± 0.2 cpm and a DP of 0.0015 ± 0.0002 mV2; 19.6 ±
3.2% of power was in the bradygastric range, 54.2 ± 3.3%
of power was in the normogastric range, and 24.1 ± 2.6%
of power was in the tachygastric range. The administra-
tion of saline did not affect significantly any of the cardio-
vascular parameters that were measured, or core body
temperature (n = 8, Figure 6A-D) and did not induce
emesis in any of the animals. However, the administration
Figure 3 Effect of a subcutaneous administration of exendin-4
(30 nmol/kg) and/or exendin (9–39) (300 nmol/kg) on blood
glucose levels following an intraperitoneal glucose load
(1.5 g/kg, i.p.). (A) Blood glucose levels at t = −15 min to 120 min
after administration of exendin (9–39) (300 nmol/kg) or saline
(0.5 ml/kg) followed 15 min later by exendin-4 (30 nmol/kg) or saline
(0.5 ml/kg) and a glucose load (1.5 g/kg, i.p.). (B) The area under the
glycaemic curves between t = −15 and 0 min. (C) The area under
the glycaemic curves between t =0 and 120 min. Sal = saline,
Ex-4 = exendin-4, Ex-9 = exendin (9–39). 1. Ex-9 (300 nmol/kg, s.c.)
or Sal (0.5 ml/kg, s.c.), 2. Ex-4 (30 nmol/kg, s.c.) or Sal (0.5 ml/kg, s.c.)
+ glucose (1.5 g/kg, i.p.). Data represents the mean ± s.e.m. of 3
animals. Significant differences are shown as *P <0.05, **P <0.01
(one-way ANOVA followed by Bonferroni test).
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(4 episodes of 26 retches and 4 vomits with a latency
36 min ) in one out of nine ferrets but decreased heart rate
variability during the first hour following exendin-4 ad-
ministration in all animals (P < 0.001; n =8, Figure 6C). In
the ferret exhibiting emesis, there was an associated in-
crease in mean arterial blood pressure and heart rate
(approximately 30 bpm increase) with a corresponding
trend for a decrease in body temperature (approximately
0.7°C fall, i.e. similar to that seen in animals without
emesis); there was also a decrease in HRV (data not
shown). Inspection of the electrogastrogram revealed that
in the ferret exhibiting emesis, there was a shift towards
bradygastria, and a reduction of power compared with an-
imals that did not exhibit emesis following treatment with
exendin-4 or saline (Figure 7). On presentation of food at
t = 240 min, all of the saline-treated animals ate (8/8). Con-
versely, none of the animals (0/9) treated with exendin-4
ate. In the saline treated-animals that ate there was a con-
sequent decrease of DF from approximately 9.8 cpm to
8.5 cpm with an increase in the % power of bradygastria
from approximately 20% to 40% (P < 0.01; n = 8, Figure 6E
and F).
Discussion
The present studies are the first to demonstrate the ability
of exendin-4 to lower blood glucose levels and inhibit
feeding in the ferret. In the majority of animals, the effects
occurred in the absence of a major action on cardiovascu-
lar or on gastric myoelectric activity (GMA). However,
exendin-4 has a low emetic potential demonstrated by a
single animal with brief retching and vomiting episodes.
In this animal, there was a transient increase in BP and a
disrupted GMA exemplified by a reduction of power and
a shift towards bradygastria. This is in contrast to the
bradygastria seen following eating, where there was a clear
increase in power.
The activity of exendin-4 to lower blood glucose appears
to be conserved across several species including diabetic
mice [33], diabetic rats [34], Suncus murinus [19], healthy
human subjects [35], and patients with type 2 diabetes [4].
In our studies, the specificity of the action of exendin-4
was confirmed using exendin (9–39), the GLP-1 receptor
antagonist, which also elevated blood glucose levels alone
suggesting that GLP-1 receptors are tonically active, and
their activation lowers blood glucose. Indeed, exendin
(9–39) is reported to correct fasting hypoglycaemia in
SUR-1−/− mice, which are hypoglycaemic when fasted
and hyperglycaemic when glucose-loaded [36]. Con-
versely, the role of GLP-1 receptors in control of gastro-
intestinal motility is unclear and this may relate to species
differences. There is no doubt in man that GLP-1 receptor
activation in vivo inhibits gastric emptying [5] and small
bowel motility [6], thereby reducing metabolic demand in
Figure 4 Effects of feeding on gastric myoelectric activity. (A) Running spectrum analysis of no food presented after fasting; (B) running
spectrum analysis of food presented after fasting. Each horizontal line represents 10 min of data. The red lines represent the period of free
feeding; the black lines represent the period of fasting; and the blue lines represent the period of food or no food.
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the mouse GLP-1 receptor activation relaxes carbachol-
pre-contracted circular muscle strips of gastric antrum but
not the fundus [40], while it inhibits the EFS-evoked circu-
lar contraction of the duodenum but not longitudinal con-
tractions of isolated tissues [41]. Both effects are via an
action on GLP-1 receptors in the enteric nervous system,
probably via the release of nitric oxide [40]. In contrast in
Suncus murinus, exendin-4 dose-dependently contracts iso-
lated longitudinal ileum via the enteric nervous system and
an involvement of muscarinic receptors [18]. Studies on
isolated smooth muscle cells from the human colon show
that GLP-1 (7–36) induces a weak contractile response that
is abolished by exendin (9–39) amide [42]. However, GLP-1
failed to contract the circular antrum and corpus muscles
in rats, but delayed gastric emptying via mechanisms prob-
ably involving the sympathetic system [16]. In the present
studies, exendin-4 failed to either contract or relax isolated
segments of the ileum (a similar lack of effect was also seen
of antrum, duodenum, jejunum, colon tissues), even though
GLP-1 receptors were detected in all areas of the GI tractthat were investigated. The lack of response was unex-
pected given that we detected GLP-1 receptors in all re-
gions of the gastrointestinal tract examined and the brain.
Certainly, in other studies using similar methodology, GLP-
1 receptors have been found in the pancreatic islets, lung,
heart, gastrointestinal tract, and various brain areas, and
GLP-1 receptor levels is highest within the phylogenetically
oldest parts of the brain [43-46]. The specificity of the anti-
body for the ferret GLP1R receptor(s) is not known but
the receptor is highly conserved with high inter- species
(mouse, rat, dog, human) homology and the “ferret
GLP1R” band appears in the same place (~53 kDa) as that
seen in the rat brain using the same antibody (data not
shown). However, it is recognised that further molecular
characterisation of the putative ferret GLP1 R is needed
before further studies of distribution and characterisation
of pharmacology can be undertaken for comparison with
other species.
More consistent data across species are seen from
studies on GLP-1 receptors and feeding. GLP-1 receptor
agonists reduce food intake across several species. In
Figure 5 Effect of food intake on gastric myoelectric activity.
(A) Dominant frequency, (B) bradygastria, (C) normogastria, and (D)
tachygastria are shown. 1. Food withdraw in both group, 2. Food
was presented to group A. Sal = saline, Ex-4 = exendin-4. Data represents
the mean ± s.e.m. of 4 animals. Significant differences are shown as
*P < 0.05, ***P< 0.001 (repeated measures two-way ANOVA followed by
Bonferroni tests).
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neous administration, but has no effect in GLP-1 receptor
knockout mice [47]. In rats, peripherally administered-
exendin-4 inhibits feeding at low doses via a vagal mech-
anism, but at higher doses the mechanism may also
involve the nucleus tractus solitarius and hypothalamus
[48]. In humans, GLP-1 is a potent regulator of food
intake [49]. Therefore, the inhibitory action of exendin-4
on feeding in ferrets was not unexpected, and is also simi-
lar to data we obtained in Suncus murinus [20]. Howexendin-4 inhibits feeding was not revealed in the present
studies, but the mechanism does not appear to involve
modulation of gastric myoelectric activity. This is particu-
larly interesting, since studies have shown that GLP-1 ago-
nists delay gastric emptying via vagal afferent inhibitory
effects on gastric motor function in rats [50,51] and fur-
ther studies have shown that GLP-1 and exendin-4-
induced gastric motility inhibition is via activation of vagal
non-adrenergic non-cholinergic (NANC) pathways and
withdrawal of cholinergic tone [52].
The incidence of nausea and emesis in man following
subcutaneously administered-exendin-4 at doses lowering
elevated blood glucose is 43.5% and 12.8%, respectively
[10]. It is interesting that the incidence of emesis (retching
and vomiting) in the ferret (11%) is similar to that in man.
This finding while interesting should be treated with a
degree of caution as although the limitations of the ferret
as a model for the assessment of anti-emetic agents par-
ticularly in ant-cancer chemotherapy are well described
[22] data on translation of emetic liability of agents to
humans is not as extensive [21] particularly in the case of
peptides (e.g. CCK-8) [21]. Whilst it questionable whether
it is possible to assess directly the effect of a drug to
induce nausea in animals [24,53], activation of GLP-1
receptors induces conditioned taste aversion [54] and pica
[55] in rats which lack an emetic reflex [14,15]. Food re-
fusal can be a symptom of nausea in humans [56] and
reduced food intake is a frequent occurrence in rats fol-
lowing administration of emetic agents [24] including
exendin-4 [55]. Exendin-4 suppressed food intake in the
ferrets in the present study but we are unable to deter-
mine if this is a primary effect on appetite or is secondary
to induction of a sensation with a function equivalent to
nausea in humans. However, in the ferret with an emetic
response, we observed a concurrent decrease in the dom-
inant frequency and a reduction in the power of slow
waves in GMA that was not seen in the exendin-4-treated
animals not exhibiting emesis. It is possible, therefore, that
the decrease in the power of the bradygastric range is
related to the mechanism of emesis, or that emesis per se,
disrupted GMA. Although changes in GMA are often as-
sociated with nausea in humans in cases where nausea is
mild such changes are not always observed [57] so the
lack of effect of exendin-4 on GMA seen in the majority
of animals does not preclude a “nausea –like” sensation
being involved in genesis of the reduced appetite.
The subcutaneous injection of exendin-4 did not have
an effect on mean arterial BP, HR, or core temperature.
However, in our studies, SDNN is used as an index to
represent HRV, and peripherally-administered exendin-4
decreased HRV during the first hour after drug injection
reflecting a reduction in cardiac vagal tone. A decrease
in HRV associated with nausea has been reported in
several studies of motion sickness in humans [26,58,59]
Figure 6 Effect of a subcutaneous administration of exendin-4 (100 nmol/kg, s.c.) on cardiovascular functions, core body temperature
and gastric myoelectric activity. (A) Mean arterial BP, (B) heart rate, (C) heart rate variability, (D) core body temperature, (E) dominant
frequency, power repartition in the (F) bradygastric, (G) normogastric and (H) tachygastric ranges are shown. 1. Injection of saline or exendin-4, 2.
Food was presented to both groups. BP = blood pressure, HR = heart rate, HRV = heart rate variability, Sal = saline, Ex-4 = exendin-4. Data represents the
mean ± s.e.m. of 8 animals. Significant differences are shown as **P < 0.01 (repeated measures two-way ANOVA followed by Bonferroni tests).
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Figure 7 Effects of a subcutaneous administration of exendin-4
(100 nmol/kg, s.c.) on gastric myoelectric activity. (A) Running
spectrum analysis of a control ferret that had received saline s.c.; (B)
running spectrum analysis of a ferret that received exendin-4 but
without emesis; (C) running spectrum analysis of a ferret that received
exendin-4 inducing four episodes of emesis. a. baseline, b. saline or
exendin-4 injection; c. during episodes of emesis. Each line represents
10 min of data.
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has been reported with the variations possibly reflecting
different stimuli and methods of analysis [27]. A decrease
in HRV from an initial increase was associated with the
onset of nausea in patients receiving anti-cancer chemo-
therapy [62].
The present study did not directly investigate the mech-
anisms involved in the effects of exendin-4 on food intake,
HRV or emesis but a direct effect on gastrointestinal mo-
tility appears unlikely based upon the lack of effect in the
in vitro studies. However, these observations do not pre-
clude an effect on gastrointestinal motility mediated byvagal efferents either a consequence of a central action of
exendin-4 (see below) or as a reflex consequence of
exendin-4 action on abdominal vagal afferents [51].
Rodent studies support a central site of action of GLP-1
receptor agonists and sites implicated in GLP-1 receptor
mediated effects on conditioned taste aversion [63], pica
[55] and reduction in food intake [55,63] have all been
shown in the present study to have GLP-1 receptors in
the ferret. A central site of action of systemically adminis-
tered exendin-4 is consistent with previous studies using
Suncus murinus as exendin-4 is more potent to induce
emesis when administered i.c.v. than it is following s.c. ad-
ministration [20]. We propose that systemically adminis-
tered exendin-4 acts on the area postrema to induce
emesis but in contrast to agents with a high emetic po-
tential (e.g. apomorphine, loperamide, cisplatin) [25,64],
the low incidence of emesis will make this impossible to
test using lesion techniques without the use of unaccept-
ably large numbers of animals. The area postrema via con-
nexions with the nucleus tractus solitarius could also be
the site at which exendin-4 acts to reduce food intake and
a decrease in HRV [24]. Interestingly, there is evidence in
the ferret that the NTS itself has GLP-1 positive neurones
[65]. However, as GLP-1 has been shown to activate
abdominal vagal afferents in the rat an action on vagal
afferents projecting to the area postrema/nucleus tractus
solitarius can not be excluded.
Conclusions
Our studies have revealed that peripherally administered
exendin-4 reduces elevated blood glucose and inhibits
feeding and has a low emetic potential in the ferret in
the absence of major effects on blood pressure, or
temperature homeostasis. A consistent decrease in HRV
was identified. When emesis occurred, there was an
increase in bradygastria and a reduction of power. It is
proposed that the effects of exendin-4 on food intake,
HRV and emesis occur by an action on the central ner-
vous system and most likely the area postrema but this
requires direct investigation. Identification of the site(s)
at which GLP-1 receptor agonists act to produce these
and the related dose–limiting toxicity of nausea will
facilitate the development of agonists with only the
desirable effects on glucose homeostasis.
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